Condition category
Circulatory System
Date applied
14/10/2016
Date assigned
20/10/2016
Last edited
12/09/2017
Prospective/Retrospective
Prospectively registered
Overall trial status
Ongoing
Recruitment status
Recruiting

Plain English Summary

Background and study aims
People living with diabetes often have to live with long-term complications of the disease. One of the most common, disabling and costly complications are foot ulcers which do not heal. Infections of diabetic foot ulcers are a major cause of amputation and death. In many cases, the infection is resistant to antibiotic treatment, which can make them very difficult to treat. The infected wounds are also slow to heal due to a layer of bacteria on the surface of the wound called biofilms. Non-thermal gas plasma (NTGP) is known to be an effective and safe treatment for chronic (long term) infected wounds and does not lead to antibiotic resistance. This type of treatment consists of a five minute ‘blast’ of gas plasma held over the infected wound. The treatment head on the device contains a patented ionization chamber that bombards Argon gas (an unreactive gas) with electrons (negatively charged particles) emitted from multiple hot electric filaments. The resulting plasma ions mix with air creating reactive agents to generate a wide, constant treatment field that is capable of treating large tissue areas. The aim of this study is to find out if NTGP is an effective treatment for diabetic foot ulcers and establish a solution to a real life situation.

Who can participate?
Adults with diabetes, who have foot ulcers where healing is stalled for at least 4 weeks.

What does the study involve?
Participants are randomly allocated to one of two groups. Those in the first group receive standard wound care dressing twice per week. This involves having the wound cleaned with sterile water or normal saline (salt water) and then dressed with the usual dressing used at that site. Those in the second group also receive standard wound care dressing twice per week with the addition of NTGP. This involves five minutes of applying argon gas directly over the wound after it has been cleaned, before it is dressed. Participants in both groups have samples taken from the wound at the start of this study and then after 4 weeks in order to measure the amount of bacteria present on the surface of the wound. Photographs are also taken every week for four weeks in order to assess healing.

What are the possible benefits and risks of participating?
Participants who receive the NTGP treatment may benefit from improved quality of life as the technology should reduce stress, trauma and recovery time. There are no notable risks involved with participating.

Where is the study run from?
Salford Royal NHS Foundation Trust (UK)

When is study starting and how long is it expected to run for?
August 2016 to January 2018

Who is funding the study?
Innovate UK (UK)
Adtec Europe Limited (EU)

Who is the main contact?
Mrs Mary McGovern
clinical@adtec.eu.com

Trial website

Contact information

Type

Public

Primary contact

Mrs Mary McGovern

ORCID ID

Contact details

Adtec Europe Limited
Unit 1 Alice Way
Hounslow
London
TW3 3UD
United Kingdom
+44 208 737 5500
clinical@adtec.eu.com

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

59178-445167

Study information

Scientific title

A randomised controlled trial to evaluate the efficacy of non-thermal gas plasma (NTGP) on sub-clinical wound infection (biofilm) in patients with diabetic foot ulcers compared to those treated with standard of care dressings

Acronym

Biofilm Project

Study hypothesis

The healing of chronic wounds that are stalled by sub clinical wound infection (biofilm) can be accelerated following intervention with non-thermal gas plasma.

Ethics approval

East Midlands - Leicester South Research Ethics Committee, 20/01/2017, ref: 16/EM/0476
Health Research Authority, 25/01/2017, IRAS project ID: 198288

Study design

Single-centre prospective randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

Hospitals

Trial type

Prevention

Patient information sheet

Not available in web format. Please use contact details to request a participant information sheet.

Condition

Chronic diabetic foot ulcers

Intervention

Participants are randomised to one of two groups using sealed, opaque sequentially numbered envelopes (SNOSE)

Intervention group: Participants receive local standard of care wound dressing (SOCD) plus 5 minutes treatment of NTGP twice weekly over a period of 30 days (4 weeks). SOCD involves cleansing the wound with sterile water or normal saline and then dressed with the local standard of care dressing e.g. Aquacel Foam non-adhesive, Aquacel Foam adhesive, Biatain foam non adhesive, Biatain Foam adhesive. NTGP involves a two minute treatment of argon gas plasma directly over the wound.

Control group: Participants only receive local standard of care wound dressing (SOCD) twice weekly. This involves cleansing the wound with sterile water or normal saline and then dressed with the local standard of care dressing e.g. Aquacel Foam non-adhesive, Aquacel Foam adhesive, Biatain foam non adhesive, Biatain Foam adhesive.

Follow up for all study participants will occur after the 4 weeks, last samples and digital photographs will be taken at this time and participants will be informed when the results of the study will be completed and published.

Intervention type

Device

Phase

Drug names

Primary outcome measures

Wound volume is measured using digital photographic imaging that will record, and measure the wound bed tissue type, wound dimensions and wound volume at baseline, 1, 2, 3 and 4 weeks.

Secondary outcome measures

1. The effect of gas plasma in regards to accelerated healing is measured using wound tissue biopsy’s and wound slough samples taken from the 60 patients at baseline and week 4
2. Presence of biofilms is measured as the numbers of bacteria and comparison to bacteria quantified from the wound surface, using wound tissue biopsy’s and wound slough samples, at baseline and week 4
3. Microbial populations are measured using digital photographic imaging, at baseline week 1, week 2, week 3, week 4 as well as wound tissue biopsy and wound slough samples at baseline and week 4

Overall trial start date

01/08/2016

Overall trial end date

31/03/2018

Reason abandoned

Eligibility

Participant inclusion criteria

Inclusion criteria as of 04/04/2017:
1. Male or female,
2. Aged 18 years and over
3. Diabetics with HbA1c less than 10% (<86mm/mol) (Amended 12/09/2017 to Diabetics with HbA1c less than 12% (<108mm/mol)) that has been recorded within the previous 3 months
4. Foot ulcers with University of Texas grade/size A1or A2 or B1* sited below the ankle including plantar, dorsal and heel ulcers
*Texas grade B1 ulcers which have symptoms consistent with mild diabetic foot infection (IDSA 2012)14 including:
4.1. Pus or inflammation
4.2. Inflammation extends less than 2cm from the wound
4.3. Infection is limited to skin/soft tissue
4.4. Systemically well
5. Ulcers with dimension 1.0cm2 – 30cm2
6. Ulcer where there is less than 40% decrease in wound surface area in the previous 4 weeks
7. Ulcer has not been present for more than 2 years
8. If foot pulses not palpable the toe brachial pressure index (TBPI) should be greater than 0.5
9. If TBPI cannot be assessed then the ankle brachial pressure index (ABPI) should be 0.8 or above
10. If ABPI is 1.3 or above the Doppler sounds should be at least biphasic

Original inclusion criteria:
1. Aged 18 years and over
2. Diabetics with HbA1c less than 10% (<86mm/mol) that has been recorded within the previous 3 months.
3. Foot ulcers with University of Texas grade/size A1, A2, B1 sited below the ankle including plantar, dorsal and heel ulcers.
4. Diabetics whose wound/ulcer currently, or in the last 7 days, has symptoms consistent with mild diabetic foot infection (IDSA 2012)14 including:
4.1. Pus or inflammation
4.2. Inflammation extends less than 2cm from the wound
4.3. Infection is limited to skin/soft tissue
4.4. Systemically well
5. Ulcers with dimension 1.0cm2 – 30cm2
6. Ulcer where there is less than 40% decrease in wound surface area in the previous 4 weeks
7. Ulcer has not been present for more than 2 years
8. Adequate blood supply determined by palpable foot pulses or if not palpable a TBPI greater than 0.7
9. Loss of protective sensation to a 10g monofilament
10. Male or female

Participant type

Patient

Age group

Adult

Gender

Both

Target number of participants

60 patients altogether. 30 patients in each arm will be randomised to receive local standard of care wound dressing (SOCD) or SOCD plus 5 minutes treatment of NTGP 5 twice weekly.

Participant exclusion criteria

Exclusion criteria as of 04/04/2017:
1. HbA1c greater than 10% (>86mm/mol) Amended 12/09/2017: to HbA1c greater than 12% (>108mm/mol)
2. Those with malignancy or other immunosuppressive diseases
3. Those receiving radiotherapy or medications that actively delay healing (e.g. steroids, antimetabolites)
4. Those whose wound/ulcer currently has symptoms consistent with moderate diabetic foot infection (IDSA 201214) – including
4.1. Pus or inflamed wound in a patient who is systemically well and/or one of the following:
4.2. Inflammation extends greater than 2cm from wound
4.3. Lymphangitis
4.4. Localised necrosis/ gangrene
4.5. Involvement of muscle, tendon, joint or bone (active osteomyelitis)
5. Those whose wound/ulcer currently has symptoms consistent with severe diabetic foot infection (IDSA, 2012) as demonstrated by:
5.1. Extensive cellulitis,
5.3. Deep abscess with or without signs of systemic toxicity (fever, vomiting, hypotension, confusion, acidosis, renal failure, severe hyperglycaemia, leucocytosis)
6. Pregnant, or breast feeding
7. Women who are of child-bearing age not using reliable contraception
8. TBPI less than 0.5
9. ABPI less than 0.8
10. If ABPI above 1.3 and vessel sounds are monophasic
11. Those who have clinical evidence of gangrene at any location
12. Those who has a medical condition that in the opinion of the investigator would make the patient an inappropriate candidate for the study
13. Those who have necrotic toes on the study ulcer foot
14. Those who have undergone surgical procedure other than debridement on the study ulcer foot within 3 weeks prior to screening
15. Study ulcer over active Charcot’s joint
16. Non study ulcer within 5.0 cm from the study ulcer at enrolment
17. Participation in other clinical study in the last 4 weeks

Original exclusion criteria:
1. HbA1c greater than 10% (>86mm/mol)
2. Those with malignancy or other immunosuppressive diseases
3. Those receiving radiotherapy or medications that actively delay healing (e.g. steroids, NSAIDS, antimetabolites)
4. Those whose wound/ulcer currently (or in the last 7 days) has symptoms consistent with moderate diabetic foot infection (IDSA 201214) – including:
4.1. Pus or inflamed wound in a patient who is systemically well and/or one of the following:
4.2. Inflammation extends greater than 2cm from wound
4.3. Lymphangitis
4.4. Localised necrosis/ gangrene
4.5. Involvement of muscle, tendon, joint or bone (active osteomyelitis)
5. Thosewhose wound/ulcer currently (or in the last 7 days) has symptoms consistent with severe diabetic foot infection (IDSA, 2012) as demonstrated by:
5.1. Extensive cellulitis,
5.2. Deep abscess with or without signs of systemic toxicity (fever, vomiting, hypotension, confusion, acidosis, renal failure, severe hyperglycaemia, leukocytosis)
6. Pregnant, or breast feeding
7. Women who are of child-bearing age not using reliable contraception
8. TBPI less than 0.7
9. Those who have clinical evidence of gangrene at any location
10. Those who have a medical condition (e.g. diabetic nephropathy) that in the opinion of the investigator would make the patient an inappropriate candidate for the study
11. Those who have necrotic toes on the study ulcer foot
12. Those who have undergone surgical procedure other than debridement on the study ulcer foot within 3 weeks prior to screening
13. Study ulcer over active Charcot’s joint
14. Non study ulcer within 5.0 cm from the study ulcer at enrolment
15. Participation in other clinical study in the last 4 weeks

Recruitment start date

06/02/2017

Recruitment end date

31/01/2018

Locations

Countries of recruitment

United Kingdom

Trial participating centre

Salford Royal Hospital
Stott Lane
Salford
M6 8HD
United Kingdom

Sponsor information

Organisation

Adtec Europe Limited

Sponsor details

Unit 1 Alice Way
Hounslow
London
TW3 3UD
United Kingdom
+44 208 737 5500
claire@adtec.eu.com

Sponsor type

Industry

Website

http://www.adtecplasma.com/

Funders

Funder type

Government

Funder name

Innovate UK

Alternative name(s)

Funding Body Type

government organisation

Funding Body Subtype

Federal/National Government

Location

United Kingdom

Funder name

Adtec Europe Limited

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer reviewed journal and at wound care conferences.

IPD Sharing plan:
The current data sharing plans for the current study are unknown and will be made available at a later date

Intention to publish date

31/05/2018

Participant level data

To be made available at a later date

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes

12/09/2017: Adtec Europe Limited has been added as a funder. Miss Claire Donohoe (claire@adtec.eu.com) has been removed as a study contact and Mrs Mary McGovern (clinical@adtec.eu.com) has been added. Recruitment end date has been updated from 03/07/2017 to 31/01/2018. Trial end date has been updated from 31/01/2018 to 31/03/2018. Intention to publish date has been updated from 31/07/2017 to 31/05/2018. Inclusion and exclusion criteria have been updated. 04/04/2017: The following changes have been made to the record: 1. The overall trial end date has been updated from 31/07/2017 to 31/01/2018 2. The recruitment dates have been updated from 14/11/2016 - 10/04/2017 to 06/02/2017 - 03/07/2017 3. The inclusion and exclusion criteria have been updated